Veterans’ PTSD crisis driven by systemic military trauma—psilocybin retreats emerge as grassroots response amid FDA caution and state-level access expansion
Original framing: “‘I didn’t want to be on medication the rest of my life’: veteran runs psilocybin retreats for PTSD before FDA approval” — The Guardian - World
The criminalization of psychedelics in the 20th century was a political tool, not a public health decision, targeting marginalized communities and suppressing Indigenous and Afro-diasporic spiritual practices. The U.S. military’s role in manufacturing PTSD through repeated deployments and inadequate mental health support is a systemic failure dating back to Vietnam. The current push for FDA approval mirrors historical patterns of pharmaceutical co-optation of traditional medicines, as seen with aspirin derived from willow bark.
The veteran PTSD crisis is not a failure of individual resilience but a structural outcome of the U.S. military’s reliance on endless war, coupled with a healthcare system that abandons its warriors upon discharge.
The psilocybin retreats emerging as grassroots solutions reflect a broader pattern of systemic neglect, where communities—often led by veterans themselves—fill the gaps left by failed institutions. This moment mirrors historical precedents, from the criminalization of peyote in the 19th century to the modern pharmaceutical co-optation of Indigenous medicines, revealing how power structures shape both the causes of trauma and its perceived solutions. The FDA’s cautious approval process, while necessary, risks repeating past mistakes by prioritizing clinical standardization over cultural context and community needs. True healing requires dismantling the military-industrial complex’s role in manufacturing trauma while centering the wisdom of those who have long used psychedelics as tools for collective liberation, not just individual relief.